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obstructive pulmonary disease (35.5%), hypertension (29.6%) 
and depression (10.4%) being the most commonly reported. 
 Conclusion: These real-world data indicate that varenicline 
is an effective and well-tolerated smoking cessation treat-
ment when used in the primary care setting including pa-
tients with smoking-related comorbidities. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Randomized controlled studies (RCTs) are the gold 
standard in proving efficacy of one pharmacotherapy 
over another or over placebo. While RCTs have excellent 
internal validity, their external validity is limited, in par-
ticular, by the exclusion of patients with severe physical 
or mental disorders, which limits the translation of re-
sults into the real world. Therefore, phase IV effectiveness 
studies are useful to confirm the findings of RCTs in the 
real-world setting  [1] .
 Varenicline has demonstrated efficacy versus placebo 
in a number of RCTs  [2–6] . According to a meta-analysis, 
at the recommended dose of 1 mg twice daily, varenicline 
increases the chances of successful long-term smoking 
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 Abstract 
 Aims: Although varenicline is commonly prescribed in pri-
mary care, information on smoking-related comorbidities 
and the effectiveness of varenicline in this context in Ger-
many is scarce. This study assessed the efficacy and safety
of varenicline in a large sample of patients seeking smoking 
cessation treatment through their general practitioners. The 
frequency of comorbidities was also evaluated.  Methods: 
This was a 12-week, prospective, observational, non-com-
parative phase IV trial conducted in Germany. Abstinence 
rates at week 12 were evaluated by verbal reporting using 
the nicotine use inventory.  Results: Overall, 1,391 subjects 
were enrolled; 1,177 received study medication and were 
evaluated for effectiveness and safety. At the end of the 
study, 71.1% (95% confidence interval 68.5–73.7) of subjects 
were abstinent. There were a total of 205 all-causality ad-
verse events; 2.2% were classified as serious or severe. There 
were no fatal adverse events. At inclusion, 66.7% of partici-
pants had at least 1 concurrent comorbidity, with chronic 
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cessation between 2- and 3-fold compared with pharma-
cologically unassisted quit attempts  [7] .
 Postmarketing safety data have included reports of de-
pressed mood, agitation and suicidal behavior or ide-
ation, and the varenicline prescribing information has 
been updated to include this information. Based on these 
post-marketing reports, questions have been raised about 
a possible association between varenicline and neuropsy-
chiatric adverse events  [8, 9] , although such data suffer 
from limitations and are not sufficient to establish a caus-
al relationship. Furthermore, surveillance reports and 
secondary analyses of trial data lend little support to a 
causal relationship  [7] . To further assess the neuropsychi-
atric safety of varenicline, a large, randomized, double-
blind placebo controlled study is ongoing (clinicaltrials.
gov identifier: NCT01456936). The prescribing informa-
tion for varenicline has also been updated to include in-
formation about a small numeric increase in the inci-
dence of certain cardiovascular events in patients taking 
varenicline compared with those taking placebo in a 
study of patients with stable cardiovascular disease  [4] . 
While a meta-analysis of cardiovascular events in vareni-
cline studies has raised questions about cardiovascular 
risk  [10] , regulators have not drawn robust conclusions 
from that analysis  [11] . A second meta-analysis did not 
report a clinically or statistically significant increase in 
the incidence of cardiovascular events in varenicline-
treated versus placebo-treated subjects  [12] .
 Smoking-related diseases such as chronic obstructive 
pulmonary disease (COPD), asthma, cardiovascular dis-
ease, diabetes mellitus and arterial hypertension are very 
common, particularly among the aging population  [13] . 
Smoking cessation is known to reduce mortality in pa-
tients with COPD  [14] , and has a profoundly positive im-
pact on asthma, cardiovascular disease  [15] , diabetes 
mellitus  [16] , arterial stiffness and presumably arterial 
hypertension  [17] . Furthermore, many patients with 
mental disorders smoke. Although it may be particularly 
difficult, these individuals can successfully quit smoking 
when they receive appropriate treatment  [18] . Assessment 
of smoking status and counseling of smokers are core 
tasks in primary care. Routine assessment of smoking 
habits is a recommended component of regular checkups 
and also forms part of disease management programs for 
patients with coronary artery disease, diabetes  [19] and 
COPD  [14] . Opportunistic assessment of smoking status 
can be conducted in patients consulting with symptoms 
or diseases related to cigarette smoking. While even brief 
advice delivered by a physician has a small but significant 
effect on cessation rates  [20] , success rates can be signifi-
cantly enhanced by more intense counseling and use of 
pharmacotherapy  [7, 21, 22] . Although there is convinc-
ing evidence on the effectiveness of smoking cessation 
therapies in the primary care setting  [23–26] , there is cur-
rently very little information available on use in patients 
with smoking-related comorbidities in the real-world set-
ting.
 The aim of this real-life study was assessment of the 
12-week cessation rate and safety profile of varenicline in 
a large sample of patients including patients with multiple 
comorbidities seeking a smoking cessation intervention 
with varenicline through their general practitioners.
 Methods 
 Study Design and Population 
 This study was a 12-week, prospective, observational, non-
comparative phase IV trial conducted in 459 mostly primary care 
practices in Germany between 27 May 2010 and 30 March 2011. 
The study (clinicaltrials.gov identifier: NCT01104636) was ap-
proved by the Ethical Board of the Freiburger Ethik Kommission 
International and written informed consent was obtained prior to 
the subjects entering the study. A schematic overview of the study 
design is shown in  figure 1 .
 Screening and Eligibility 
 Subjects were eligible for inclusion in this study if they were of 
legal age to smoke, were regular smokers (mainly cigarettes), if 
they were motivated and willing to quit and were, according to the 
clinical judgment of their personal physician, suitable candidates 
for treatment with varenicline for smoking cessation. There were 
no restrictions on prior or concomitant medications or comor-
bidities apart from the usual prescribing information in the Eu-
ropean Summary of Product Characteristics.
 Study Medication 
 Participants were prescribed varenicline for at least 12 weeks. 
The smoker determined a quit date and received a prescription for 
study medication to commence treatment up to 2 weeks before the 
quit date. Since smoking cessation is not covered by statutory 
health insurance in Germany, the cost of the drug was covered by 
the patient.
 Clinical Evaluations 
 Data were collected at three time points: baseline (week 0, ad-
ministration of the first dose of varenicline), an optional interim 
visit, and at the end of study (week 12) ( fig. 1 ). Demographic data, 
smoking history, comorbidities, medication, history of nicotine 
use, concurrent smoking-related illnesses and proposed behav-
ioral support were recorded at enrollment. Nicotine dependence 
was also assessed at enrollment using the Fagerström Test of Nic-
otine Dependence (FTND), which comprises six questions. The 
primary end point was the 7-day point prevalence of abstinence 
rate at weeks 11–12 based on verbal reporting using a nicotine use 
inventory (NUI). The NUI consisted of the following two ques-
tions: ‘Has the subject smoked any cigarettes (even a puff) in the 
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last 7 days?’ and ‘Has the subject used any other tobacco products 
(e.g. pipe, cigars, snuff, chewing tobacco) in the last 7 days?’. NUI 
assessments were also carried out at interim visits, if applicable.
 Safety Evaluations 
 Adverse events reported by investigators were coded automat-
ically using the Medical Dictionary for Regulatory Activities and 
summarized descriptively. Investigators recorded all observed or 
volunteered adverse events (including severity: mild, moderate or 
severe) and also their opinion of the relationship to the study 
treatment on case report forms. Adverse events included adverse 
drug reactions, illnesses with onset during the study and exacer-
bation of previous illnesses.
 Statistical Analysis 
 This study was non-comparative, and analyses were descriptive 
and exploratory. The analysis included all enrolled participants 
who had documented evidence of receiving at least one dose of 
study medication. Descriptive summaries were provided as counts 
and percentages for categorical variables, and as means and stan-
dard deviations for continuous variables. Evaluations were per-
formed according to the intention-to-treat principle  [27] . Patients 
who were lost to follow-up were counted as smokers. The success 
rate for smoking cessation was calculated using the number of sub-
jects who were considered to be responders for the 7-day point 
prevalence of abstinence as a proportion of the number of subjects 
included in the study, reported with Clopper-Pearson 95% confi-
dence limits and determined based on the binominal distributions. 
No dosing data were recorded for 214 subjects enrolled in this 
study. Consequently, these subjects were excluded from the main 
analyses. To ensure that exclusion of these subjects did not bias the 
results, an additional sensitivity analysis was performed including 
all subjects irrespective of whether dosing data were recorded.
 Results 
 Baseline Demographics 
 Subject disposition is detailed in  figure 2 . Overall, 
1,391 subjects were enrolled in this study, of whom, 1,177 
received study medication and were evaluated for effec-
tiveness and safety.
 A total of 999 (84.9%) subjects completed the study, 
and 157 (13.3%) subjects discontinued. The most com-
mon reasons for discontinuation were insufficient clini-
cal response (43 subjects, 3.7%) and other (including 
cost, desire to smoke, side effects; 43 subjects, 3.7%). For-
ty-nine subjects (4.2%) discontinued due to adverse 
Enrollment
Start
treatment
Quit
smoking Efficacy
assessment
Stop
treatment 
Prior to
week 0
Week 0 Weeks 1–2 Week 11 Week 12
 Fig. 1. Study design. 
15%
15%
85%
85%
 157 discontinued trial
214 no recording of dosing
data 
1,391 enrolled in study
1,177 patients for analysis of
effectiveness and safety 
1,177 patients received at 
  least one dose of
varenicline
21 subjects with
ongoing status at date
of cutoff; final status
was unknown
999 patients completed
12 weeks 
 Fig. 2. Subject disposition. The 214 patients with no recording of 
dosing data were included in an additional sensitivity analysis. 
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events. Twenty-one subjects were ongoing at the cutoff 
date (i.e. those with unknown final status at end of the 
study). The mean age of the participants was 49.4 years, 
and 57% were male. Sociodemographic characteristics of 
the participants are shown in  table 1 . The mean number 
of years of smoking was 26.6; the average number of cig-
arettes smoked per day over the past year was 22.1, and 
subjects had, on average, attempted to quit 3.6 times in 
their lifetime. The most frequently used methods for 
quitting were: ‘cold turkey’ (36.3%), nicotine patch 
(29.3%) and nicotine gum (21.1%). The main reasons stat-
ed for wanting to quit this time were: health (88.4%), for 
family/friends (39.7%) and money/cost (39.7%). The 
mean score on the Fagerström Test of Nicotine Depen-
dence was 5.3.
 Comorbidities and Concomitant Medications 
 In total, 66.7% of participants were reported to have at 
least one current comorbidity, the most common of which 
included COPD (35.5%), hypertension (29.6%), cardio-
vascular disorder (10.5%), depression (10.4%), diabetes 
mellitus (8.2%) and asthma (7.9%). The most common 
concomitant medications used during the study were: 
simvastatin (6.6%), acetylsalicylic acid (6.4%), ramipril 
(6.3%) and tiotropium bromide (6.1%).
 Duration of Study Medication 
 The median duration of treatment was 85 days (range: 
1–463). 430 of the total 1,177 participants (36.5%) took 
varenicline for a duration of between 61 and 90 days, and 
398 participants (33.8%) took study treatment for  6 91 
days. The recommended treatment period for the major-
ity of subjects (874 subjects, 84.9%) was  6 12 weeks. A 
total of 823 of 1,057 participants (77.9%) received smok-
ing cessation counseling in addition to study medication; 
11.4% received minimal ( ! 3 min) counseling, and 44.8% 
received low-intensity (3–10 min) counseling. 1,066 of the 
1,177 treated subjects (90.6%) attended optional interim 
visits during weeks 3–11.
 Abstinence Rates 
 In the 7-day period between weeks 11 and 12 (end of 
study), 837 of the 1,177 participants (71.1%; 95% confi-
dence interval 68.5–73.7) were abstinent. Additional 
analyses were performed to include the 214 subjects for 
whom no dosing data were recorded and who were ex-
cluded from the main analysis. For subjects with no dos-
ing data recorded, the earliest case report form date was 
used as the subject’s dosing date to include them in the 
treated population. A total of 1,391 subjects were included 
in these additional sensitivity analyses; 1,040 (74.8%) 
subjects completed the study, and 191 (13.7%) subjects 
discontinued. The results of these additional sensitivity 
analyses were similar to the results from the main analy-
ses. The proportion of responders at week 12 was 62.5% 
(n = 869/1,391; 95% confidence interval 59.9–65.0).
 Safety 
 A total of 205 all-causality adverse events were report-
ed in 130 subjects (11.0%) during the study, of which 189 
(in 122 participants, 10.4%) were considered treatment-
related.
 Forty-nine subjects (4.2%) permanently discontinued 
due to adverse events; 3.7% were considered treatment-
related by the investigators. Most adverse events were 
classified as mild (42/1,177, 3.6%) or moderate (126/1,177, 
10.7%) in severity. Mild adverse events were defined as 
those that did not interfere with subject’s usual function, 
moderate as those which interfered to some extent with 
subject’s usual function, and severe as those that inter-
fered significantly with subject’s usual function. Severe 
adverse events were reported in 19 participants (1.6%). 
Severe adverse events included suicidal ideation, depres-
sion and hallucination. Seven participants (0.6%) experi-
enced 17 serious adverse events (14 of which were consid-
ered treatment related by the investigators: aggression, 
Table 1.  Baseline sociodemographic data (n = 1,177)
Subjects1
Sex 1,172
Male 669 (57%)
Female 503 (43%)
Age, years
Mean 
Range
1,161
49.4 (12)
18.0–81.0
Weight, kg 1,146 77.5 (15.8)
Body mass index, kg/m2 1,144 25.9 (4.4)
Marital status
Married
1,112
62.1%
Educational level
Without education (up to 9 years)
With education (9–17 years)
University degree (117 years)
886
105 (11.9%)
748 (84.4%)
33 (3.7%)
Employment status
Full-time
Part-time
Not employed
1,102
737 (66.9%)
101 (9.2%)
264 (24.0%)
F igures in parentheses for age, weight and body mass index 
indicate SD. 1 Number of subjects with available data.
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depression/depressed mood, suicidal ideation (each n = 
2); apathy, abnormal dreams, hallucination, loss of con-
sciousness, mood swings, myalgia, nausea, road traffic 
accident (each n = 1). There were no fatal adverse events. 
The most frequently reported ( 6 1%) treatment-emergent 
adverse events (all-causality) are summarized in  table 2 , 
and all neuropsychiatric adverse events are summarized 
in  table 3 .
 Discussion 
 This was an observational study designed to assess the 
efficacy and safety of varenicline when used in the real-
world setting in Germany. At the end of the treatment 
period (week 12), the 7-day point prevalence of abstinence 
was 71.1%. Varenicline was generally well tolerated, and 
no new safety concerns were identified. Most adverse 
events were mild in severity, and around 4% of partici-
pants discontinued the study because of adverse events. 
Severe adverse events were observed in 1.6% of subjects. 
It is important to note that there was a high percentage of 
smoking-related disease in this study population; 35.5% 
of participants had COPD, 10.5% had cardiovascular dis-
order, 8.2% had diabetes mellitus, 10.4% had depression 
and 7.9% had asthma.
 In this real-world study, the end-of-treatment 7-day 
point prevalence of abstinence in smokers who received 
varenicline (71%) was higher than abstinence rates ob-
served in RCTs. The reported 7-day point prevalence of 
abstinence rate at week 12 was approximately 50% in 
RCTs of varenicline healthy smokers  [2, 3] , 54% in a co-
hort with cardiovascular disease  [4] , and 48% in a popu-
lation of smokers with COPD  [5] . In a recent 12-week, 
observational, non-comparative study of varenicline 
conducted in 566 participants from four European coun-
tries, 64.6% of participants had successfully quit smoking 
by the end of the treatment phase at week 12  [26] , and 
similarly, other studies reported 12-week, point preva-
lence of abstinence rates of 64  [28] and 62%  [29] .
 According to results of a meta-analysis, smoking ces-
sation rates are approximately twice as high when vareni-
cline treatment is administered for 24 weeks versus 6 
weeks  [30] . In the present study, varenicline was not re-
imbursed, and the costs for a 4-week treatment initiation 
pack or a 4-week maintenance pack were EUR 109.96. 
Despite this, the median duration of treatment with va-
renicline was 85 days and comparable with that of previ-
ous RCTs  [2–5] (median duration, 84 days). Similarly, in 
the European observational study mentioned above, the 
median duration of treatment was 82.5 days  [26] .
 The observed high smoking cessation rate in our co-
hort could be explained by selection of subjects with rela-
tively high motivation to quit smoking, for example ow-
ing to the presence of symptomatic morbidity or because 
they were responsible for meeting the costs of medication, 
which their counterparts in phase III studies were not. It 
has been shown that copayment has strong deterrent ef-
fect on smoking  [31] . Selection of motivated individuals 
for interventions is a typical pragmatic approach in pri-
mary care.
 The most commonly observed adverse event in vareni-
cline RCTs was nausea, which was reported at rates in the 
range of 29  [2, 3] to 40%  [32] , with attributable discon-
tinuation rates ranging from 2.5 to 7.6%  [7] . Other ad-
verse effects associated with varenicline include insom-
Table 2.  Incidence of treatment-emergent adverse events (all-
causality) occurring in ≥1% of all participants (n = 1,177)
Total Mild Moderate Severe
Nausea 41 (3.5) 14 (1.2) 18 (1.5) 9 (0.8)
Depression 24 (2.0) 1 (0.1) 21 (1.8) 2 (0.2)
Headache 16 (1.4) 4 (0.3) 12 (1.0) 0 (0.0)
Flatulence 15 (1.3) 0 (0.0) 15 (1.3) 0 (0.0)
Hyposomnia 15 (1.3) 0 (0.0) 15 (1.3) 0 (0.0)
Figures in parentheses indicate percentages.
Table 3.  Incidence of treatment-emergent psychiatric adverse 
events (all-causality; n = 1,177)
Total Mild Moderate Severe
Depression/
depressed mood
25 (2.1) 1 (0.1) 22 (1.9) 2 (0.2)
Sleep disorders and
disturbances
32 (2.7) 6 (0.5) 24 (2.0) 2 (0.2)
Apathy 3 (0.3) 0 (0.0) 2 (0.2) 1 (0.1)
Hallucination 2 (0.2) 0 (0.0) 0 (0.0) 2 (0.2)
Aggression 2 (0.2) 0 (0.0) 1 (0.1) 1 (0.1)
Suicidal ideation 2 (0.2) 0 (0.0) 0 (0.0) 2 (0.2)
Nervousness 1 (0.1) 0 (0.0) 1 (0.1) 0 (0.0)
Panic attack 1 (0.1) 0 (0.0) 0 (0.0) 1 (0.1)
Psychotic disorder 1 (0.1) 0 (0.0) 0 (0.0) 1 (0.1)
Mood swing 1 (0.1) 0 (0.0) 0 (0.0) 1 (0.1)
Figures in parentheses indicate percentages.
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nia, headache and abnormal dreams  [7] . In the two phase 
III RCTs comparing varenicline, bupropion and placebo, 
an average of 9.5% of participants in the varenicline 
groups discontinued treatment owing to adverse events 
(but remained in the trial for follow-up), compared with 
an average of 8% in the placebo groups  [7] . In a European 
observational study with over 500 subjects that had a sim-
ilar design to the present study, 19 participants (3.4%) dis-
continued the study owing to treatment-related adverse 
events. The most frequently reported adverse events for 
the total population were nausea (8.9%), insomnia (2.9%), 
and sleep disorders (2.2%)  [26] . In a study comparing 
three forms of behavioral support for smoking cessation 
in over 1,000 patients receiving varenicline for smoking 
cessation, after 1 month, 17% of participants had discon-
tinued varenicline, the majority (53%) because of adverse 
events  [33] , which may have been attributed to the Web- 
and telephone-based interventions being investigated. In 
the present study, nausea was reported in only 3.5% of 
subjects and depression in 2.0% of subjects (only one sub-
ject had reports of depression in their medical history or 
at baseline). Although nausea was less commonly report-
ed than in previous studies, other than the well-known 
fact that in general adverse events are often underreport-
ed in observational studies, we do not have an explana-
tion for this finding. Similar to studies included in the 
recent Cochrane meta-analysis  [7] and similarly to the 
European observational study  [26] , no fatal adverse events 
were recorded in the present study.
 Depression as an adverse event after quitting was re-
ported in about 2% of the patients in this study, although 
comorbid depression was present in about 10% on inclu-
sion. This is less than the  1 20% incidence previously re-
ported in patients with a history of major depression 
(who had not used antidepressant medicine for 6 months) 
 [34] and figures reported in a recent meta-analysis of sui-
cidal behavior and depression in individuals using smok-
ing cessation therapy  [9] . It is not possible to definitively 
determine whether these findings are due to the patients 
included or an underreporting known to be present in 
observational studies.
 Compared with the subject populations enrolled in 
the phase III studies investigating smoking cessation 
pharmacotherapy in healthy smokers  [2, 3, 32, 35] , par-
ticipants in the present study had a high prevalence of 
COPD, cardiovascular disease and other comorbidities. 
It is well established that the pathogenesis of these non-
communicable diseases is linked to cigarette smoking 
and, as such, smoking cessation is a crucial factor in the 
treatment of these diseases  [36] . In previous studies of 
comparable design with the present study, comorbidity 
data have been scarcely reported. In the recently pub-
lished European observational study, the most common-
ly reported prior or concomitant comorbidities were hy-
pertension (20.0%), COPD (18.2%), depression (9.4%) and 
other psychiatric disorders (3.3%)  [26] . According to data 
from a representative US survey, persons with a mental 
disorder consume more than 40% of the total cigarettes 
smoked, the highest percentage in patients suffering from 
depression  [37] . In a large UK smoking cessation cohort, 
a history of mental health disorder was present in 4% of 
participants, and 25% were receiving antidepressant 
therapy  [24] . In the present study, 10.4% of participants 
had depression, and 5.7% had other mental disorders. 
The results of the present study confirm previous find-
ings showing that patients with mental disorders includ-
ing depression can successfully quit smoking with the aid 
of smoking cessation pharmacotherapy  [18] .
 Strengths and Limitations 
 This is the largest observational study of the efficacy 
and safety of varenicline for smoking cessation. Strengths 
of this study are that it included patients with multiple 
comorbidities who were not included in the initial clini-
cal trials of smoking cessation, and the low level of sup-
port received by the patients adds to the generalizability 
of the results. Several limitations have also to be acknowl-
edged. We do not have biologic confirmation of smoking 
status, for example through measurement of carbon 
monoxide concentration in exhaled breath. However, 
self-report has been shown to reliably capture smoking 
status  [38, 39] . Furthermore, follow-up was only 12 weeks, 
whereas a follow-up of 56 weeks would have been supe-
rior and is standard in RCTs  [27] . The comorbidity as re-
ported by the practices was not confirmed by an indepen-
dent investigator. However, we have no reason to assume 
that the provided data on comorbidity are not valid.
 Although the present study sample comprises partici-
pating practices which are likely highly motivated to as-
sess patients for smoking cessation, it is unlikely that the 
patient population in this study differs from other prac-
tices. Selection bias of patients highly motivated to quit 
smoking is possible, but motivation to quit is considered 
a prerequisite for all pharmacologic intervention for this 
addiction. It should also be acknowledged that in our 
study, patients had to pay for the medication themselves, 
and this may limit extrapolation of our findings to other 
healthcare settings.
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 Conclusions 
 The results of this study demonstrate that varenicline 
is an effective and well-tolerated smoking cessation ther-
apy when used in ambulatory care including patients 
with frequent comorbidities. The quit rates observed in 
this real-life study in patients treated with varenicline 
were higher than in RCTs; however, inter-study compar-
isons should be interpreted with caution. Future studies 
should assess the long-term effectiveness of varenicline 
beyond 12 weeks.
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